|Bid||2.5500 x 1400|
|Ask||0.0000 x 800|
|Day's Range||2.6600 - 2.7900|
|52 Week Range||1.0800 - 7.2500|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Acer Therapeutics Inc. (NYSE: ACER) related to the company's statements about its discussions with the U.S. Food and Drug Administration for Acer's EDSIVO drug candidate. The FDA later rejected Acer's New Drug Application for EDSIVO in June 2019.
ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...